Multidrug Resistance-associated Protein Gene Overexpression and Reduced Drug Sensitivity of Topoisomerase II in a Human Breast Carcinoma MCF7 Cell Line Selected for Etoposide Resistance

Cancer Research

Volumn 54, Issue 1, 1994, Pages 152-158

  Schneider, Erasmus ^a   Horton, Julie K ^a,b   Yang, Chih Hsin ^a   Nakagawa, Masayuki ^a   Cowan, Kenneth H ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMSACRINE; CAMPTOTHECIN; CHLORAMBUCIL; DNA TOPOISOMERASE (ATP HYDROLYSING); DOXORUBICIN; EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; GENISTEIN; MELPHALAN; MEMBRANE PROTEIN; MITOXANTRONE; TENIPOSIDE; VINCRISTINE;

ARTICLE; BREAST CARCINOMA; CARCINOMA CELL; DRUG CROSS REACTIVITY; DRUG SENSITIVITY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; MULTIDRUG RESISTANCE; PRIORITY JOURNAL;

BREAST NEOPLASMS; CARRIER PROTEINS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE; ETOPOSIDE; FEMALE; HUMANS; MEMBRANE GLYCOPROTEINS; P-GLYCOPROTEIN; RNA, MESSENGER; TENIPOSIDE; TUMOR CELLS, CULTURED;

EID: 0028009810     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: None     Document Type: Article

References (58)

1. Beck, W. T. Mechanisms of multidrug resistance in human tumor cells. The roles of P-glycoprotein, DNA topoisomerase II, and other factors. Cancer Treat. Rep. 17: 11–20, 1990.
2. Endicott, J. A., and Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 58: 137–171, 1989.
3. Gottesman, M. M., and Pastan, I. Biochemistry of multidrug resistance mediated by the multidrug transporter. Annu. Rev. Biochem. 62: 385–427, 1993.
4. McClean, S., and Hill, B. T. An overview of membrane, cytosolic and nuclear proteins associated with the expression of resistance to multiple drugs in vitro. Biochim. Biophys. Acta, 1114: 107–127, 1992.
5. Cole, S. P. C. Bhardwaj, G. Gerlach, J. H. Mackie, J. E. Grant, C. E. Almquist, K. C. Stewart, A. J. Kurz, E. U. Duncan, A. M. V., and Deeley, R. G. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science, 258: 1650–1654, 1992.
6. Cole, S. P. C. Patterns of cross resistance in a multidrug-resistant small-cell lung carcinoma cell line. Cancer Chemother. Pharmacol. 26: 250–256, 1990.
7. Cole, S. P. C. Chanda, E. R. Dicke, F. P. Gerlach, J. H., and Mirski, S. E. L. Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II. Cancer Res. 51: 3345–3352, 1991.
8. Mirski, S. E. L. Gerlach, J. H., and Cole, S. P. C. Multidrug resistance in a human small cell lung cancer cell line selected in Adriamycin. Cancer Res. 47: 2594–2598, 1987.
9. Danks, M. K. Yalowich, J. C., and Beck, W. T. Atypical multiple drug resistance in a human leukemic cell line selected for resistance to teniposide (VM-26). Cancer Res. 47: 1297–1301, 1987.
10. Danks, M. K. Schmidt, C. A. Cirtain, M. C. Suttle, D. P., and Beck, W. T. Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26. Biochem. 27: 8861–8869, 1988.
11. Charcosset J-Y. Saucier J. M., and Jacquemin-Sablon, A. Reduced DNA topoisom-erase 11 activity and drug-stimulated DNA cleavage in 9-hydroxyellipticine resistant cells. Biochem. Pharmacol. 37: 2145–2149, 1988.
12. Per, S. R. Mattern, M. R. Mirabelli, C. K. Drake, F. H. Johnson, R. K., and Crooke, S. T. Characterization of a subline of P388 leukemia resistant to amsacrine: evidence of altered topoisomerase II function. Mol. Pharmacol. 32: 17–25, 1987.
13. Glisson, B. Gupta, R. Hodges, P., and Ross, W. Cross-resistance to intercalating agents in an epipodophyllotoxin-resistant Chinese hamster ovary cell line: evidence for a common intracellular target. Cancer Res. 46: 1939–1942, 1986.
14. Glisson, B. Gupta, R. Smallwood-Kentro, S., and Ross, W. Characterization of acquired epipodophyllotoxin resistance in a Chinese hamster ovary cell line: loss of drug-stimulated DNA cleavage activity. Cancer Res. 46: 1934–1938, 1986.
15. Zwelling, L. A. Hinds, M. Chan, D. Mayes, J. Sie, K. L. Parker, E. Silberman, L. Radcliffe, A. Beran, M., and Blick, M. Characterization of an amsacrine-resistant line of human leukemia cells. Evidence for a drug-resistant form of topoisomerase II.J. Biol. Chem. 264: 16411–16420, 1989.
16. Matsuo, K-I., Kohno, K. Takano, H. Sato S-I. Kiue, A., and Kuwano, M. Reduction of drug accumulation and DNA topoisomerase II activity in acquired teniposide-resistant human KB cell lines. Cancer Res. 50: 5819–5824, 1990.
17. Deffie, A. M. Batra, J. K., and Goldenberg, G. J. Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensitive and -resistant P388 leukemia cell lines. Cancer Res. 49: 58–62, 1989.
18. Giaccone, G. Gazdar, A. F. Beck, H. Zunino, E., and Capranico, G. Multidrug sensitivity phenotype of human lung cancer cells associated with topoisomerase II expression. Cancer Res. 52: 1666–1674, 1992.
19. Webb, C. D. Latham, M. D. Lock, R. B., and Sullivan, D. M. Attenuated topoisomerase II content directly correlates with a low level of drug resistance in a Chinese hamster ovary cell line. Cancer Res. 51: 6543–6549, 1991.
20. DeJong, S. Zijlstra, J. G. DeVries, E. G. E., and Mulder, N. H. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res. 50: 304–309, 1990.
21. Deffie, A. M. Bosman, D. J., and Goldenberg, G. J. Evidence for a mutant allele of the gene for DNA topoisomerase II in Adriamycin-resistant P388 murine leukemia cells. Cancer Res. 49: 6879–6882, 1989.
22. Bugg, B. Y. Danks, M. K. Beck, W. T., and Suttle, D. P. Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide. Proc. Natl. Acad. Sci. USA, 88: 7654–7658, 1991.
23. Hinds, M. Deisseroth, K. Mayes, J. Altschuler, E. Jansen, R. Ledley, F. D., and Zwelling, L. A. Identification of a point mutation in the topoisomerase II gene from a human leukemia cell line containing an amsacrine resistant form of topoisomerase II. Cancer Res. 51: 4729–4731, 1991.
24. Lee M-S. Wang, J. C., and Beran, M. Two independent amsacrine-resistant human myeloid leukemia cell lines share an identical point mutation in the 170 kDa form of human topoisomerase II.J. Mol. Biol. 223: 837–843, 1992.
25. Chan, V.T.-W., Ng, S. W. Eder, J. P., and Schnipper, L. E. Molecular cloning and identification of a point mutation in the topoisomerase II cDNA from an etoposide-resistant Chinese hamster ovary cell line. J. Biol. Chem. 268: 2160–2165, 1993.
26. Patel, S., and Fisher, L. M. Novel selection and genetic characterization of an etoposide-resistant human leukaemic CCRF-CEM cell line. Br. J. Cancer, 67: 456–463, 1993.
27. Danks, M. K. Warmoth, M. R. Friche, E. Granzen, B. Bugg, B. Y. Harker, W. G. Zwelling, L. A. Futschei, B. W. Suttle, D. P., and Beck, W. T. Single-strand conformational polymorphism analysis of the MT 170, 000 isozyme of DNA topoisomerase II in human tumor cells. Cancer Res. 53: 1373–1379, 1993.
28. DeVore, R. F. Corbett, A. H., and Osheroff, N. Phosphorylation of topoisomerase II by casein kinase II and protein kinase C: effects on enzyme-mediated DNA cleavage/ religation and sensitivity to the antineoplastic drugs etoposide and 4′-(9-acridinyl-amino)methane-sulfon-m-anisidide. Cancer Res. 52: 2156–2161, 1992.
29. Takano, H. Kohno, K. Ono, M. Uchida, Y., and Kuwano, M. Increased phosphorylation of DNA topoisomerase II in etoposide-resistant mutants of human cancer KB cells. Cancer Res. 51: 3951–3957, 1991.
30. Watanabe, Y. Takano, H. Kiue, A. Kohno, K., and Kuwano, M. Potentiation of etoposide and vincristine by two synthetic 1, 4-dihydropyridine derivatives in multi-drug-resistant and atypical multidrug-resistant human cancer cells. Anti-Cancer Drug Design, 6: 47–57, 1991.
31. Nakagawa, M. Schneider, E. Dixon, K. H. Horton, J. Kelley, K. Morrow, C., and Cowan, K. H. Reduced intracellular drug accumulation in the absence of P-glyco-protein (mdr\) overexpression in mitoxantrone-resistant MCF-7 breast cancer cells. Cancer Res. 52: 6175–6181, 1992.
32. Ferguson, P. J. Stephenson, M. H. Li, D. Zhou, B., and Cheng, Y Combined modalities of resistance in etoposide-resistant human KB cell lines. Cancer Res. 48: 5956–5964, 1988.
33. Fairchild, C. R. Ivy, S. P. Kao-Shan C-S. Whang-Peng, J. Rosen, N. Israel, M. A. Melera, P. W. Cowan, K. H., and Goldsmith, M. E. Isolation of amplified and overexpressed DNA sequences from Adriamycin-resistant human breast cancer cells. Cancer Res. 47: 5141–5148, 1987.
34. Akiyama, S. Fojo, S. Hanover, J. A. Pastan, I., and Gottesmann, M. M. Isolation and genetic characterization of human KB cell lines resistant to multiple drugs. Somat. Cell Mol. Genet. 11: 117–126, 1985.
35. Woodman, P. W. Williams, R. L., and Edwards, H. H. Heterogeneity in cell populations established from a human colon adenocarcinoma xenograft. In vitro, 16: 211, 1980.
36. Skehan, P. Storeng, R. Scudiero, D. Monks, A. McMahon, J. Vistica, D. Warren, J. T. Bokesch, H. Kenney, S., and Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening, J. Natl. Cancer Inst. 82: 1107–1112, 1990.
37. Smith, P. K. Krohn, R. I. Hermanson, G. T. Mallia, A. K. Gartner, F. H. Proven-zano, M. D. Fujimoto, E. K. Goeke, N. M. Olson, B. J., and Klenk, D. C. Measurement of protein using bicinchoninic acid. Anal. Biochem. 150: 76–85, 1985.
38. Schneider, E. Darkin, S. J. Robbie, M. A. Wilson, W. R., and Ralph, R. K. Mechanism of resistance of non-cycling mammalian cells to 4′-[9-acridinylamino]mefhane-sulphon-m-anisidide: role of DNA topoisomerase II in log-and plateau-phase CHO cells. Biochim. Biophys. Acta, 949: 264–272, 1988.
39. Chomczynski, P., and Sacchi, N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal. Biochem. 162: 156–159, 1987.
40. Chou, Q. Russel, M. Birch, D. E. Raymond, J., and Bloch, W. Prevention of pre-PCR mis-priming and primer dimerization improves low copy number amplifications. Nucleic Acids Res. 20: 1717–1724, 1992.
41. D'Arpa, P. Machlin, P. S. Ratrie, H. Rothfield, N. E. Cleveland, D. W., and Earnshaw, W. C. cDNA cloning of human DNA topoisomerase I: Catalytic activity of a 67.7-kDa carboxyl-terminal fragment. Proc. Natl. Acad. Sci. USA, 85: 2543–2547, 1988.
42. Chung, T. D. Y. Drake, F. H. Tan, K. B. Per, S. R. Crooke, S. T., and Mirabelli, C. K. Characterization and immunological identification of cDNA clones encoding two human DNA topoisomerase II isozymes. Proc. Natl. Acad. Sci. USA, 86: 9431–9435, 1989.
43. Arcari, P. Martinelli, R., and Salvatore, F. The complete sequence of a full length cDNA for human liver glyceraldehyde-3-phosphate dehydrogenase: Evidence for multiple mRNA species. Nucl. Acids Res. 12: 9179–9189, 1984.
44. Murphy, L. D. Herzog, C. E. Rudick, J. B. Fojo, A. T., and Bates, S. E. Use of the polymerase chain reaction in the quantitation of mdr-1 gene expression. Biochem. 29: 10351–10356, 1990.
45. Sambrook, J. Fritsch, E. E., and Maniatis, T. Molecular Cloning: A Laboratory Manual. Ed. 2. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1989.
46. Bradford, M. M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72: 248–254, 1976.
47. Harker, W. G. Slade, D. L. Drake, F. H., and Parr, R. L. Mitoxantrone resistance in HL-60 leukemia cells—reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II S-isoform. Biochemistry, 30: 9953–9960, 1991.
48. Harker, W. G. Slade, D. L. Dalton, W. S. Meltzer, P. S., and Trent, J. M. Multidrug resistance in mitoxantrone selected HL-60 leukemia cells in the absence of P-glyco-protein overexpression. Cancer Res. 49: 4542–4549, 1989.
49. Sullivan, D. M. Latham, M. D. Rowe, T. C., and Ross, W. E. Purification and characterization of an altered topoisomerase II from a drug-resistant Chinese hamster ovary cell line. Biochemistry, 28: 5680–5687, 1989.
50. Estey, E. H. Silberman, L. Beran, M. Andersson, B. S., and Zwelling, L. A. The interaction between nuclear topoisomerase II activity from human leukemia cells, exogenous DNA and 4′-(9-acridinylamino)methanesulfon-m-anisidide (mAMSA) or 4-6-O-ethylidene-β-D-glucopyranoside) (VP-16) indicates the sensitivity of the cells to the drugs. Biochem. Biophys. Res. Commun. 144: 787-793, 1987.
51. Sinha, B. K., and Eliot, H. M. Etoposide-induced DNA damage in human tumor cells—requirement for cellular activating factors. Biochim. Biophys. Acta, 1097: 111–116, 1991.
52. Zwelling, L. A. Slovak, M. L. Doroshow, J. H. Hinds, M. Chan, D. Parker, E. Mayes, J. Sie, K. L. Meltzer, P. S., and Trent, J. M. HT1080/DR4: a P-glycoprotein negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II reactive drugs despite the presence of a drug sensitive topoisomerase II.J. Natl. Cancer Inst. 82: 1553–1561, 1990.
53. Sehested, M. Friche, E. Jensen, P. B., and Demant, E. J. F. Relationship of VP-16 to the classical multidrug resistance phenotype. Cancer Res. 52: 2874–2879, 1992.
54. Sinha, B. K. Haim, N. Dusre, L. Kerrigan, D., and Pommier, Y DNA strand breaks produced by etoposide (VP-16, 213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action. Cancer Res. 48: 5096–5100, 1988.
55. Politi, P. M. Arnold, S. T. Felsted, R. L., and Sinha, B. K. P-glycoprotein-indepen-dent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. Mol. Pharmacol. 37: 790–796, 1990.
56. Yalowich, J. G., and Ross, W. E. Verapamil-induced augmentation of etoposide accumulation in L1210 cells in vitro. Cancer Res. 45: 1651–1656, 1985.
57. Slovak, M. L. Ho, J. P. Bhardwaj, G. Kurz, E. U. Deeley, R. G., and Cole, S. P. C. Localization of a novel multidrug resistance associated gene in the HT1080/DR4 and H69AR human tumor cell lines. Cancer Res. 53: 3221–3225, 1993.
58. Zaman, G. J. R. Versantvoort, C. H. M. Smit, J. J. M. Eijdems, W. H. M. deHaas, M. Smith, A. J. Broxterman, H. J. Mulder, N. H. deVries, E. G. E. Baas, F., and Borst, P. Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res. 53: 1747–1750, 1993.